ChartMill · Aug 14, 2026
Vericel (NASDAQ:VCEL): A Strong Growth Play With an Improving Technical Setup
Vericel (VCEL) combines strong growth & profitability with a promising technical setup, making it a standout Strong Growth breakout pick.
VC
NASDAQ · VCEL
Vericel Corporation
Healthcare · Biotechnology
$40.19
Down-$0.28 (-0.69%)
Updated Sep 6, 2026, 4:56 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.89B
- P/E ratio
- 144.38
- Dividend yield
- 0.00%
- 52-week range
- $28.95 – $49.32
- Volume
- 312.91K
- Avg. volume
- 728.95K
Price performance
VCEL price history
1M range · 20 trading sessions · Daily adjusted prices
VCEL closed at $40.19 after 20 trading sessions, down 8.56% for the selected period.
- Last close
- $40.19
- Period change
- -8.56%
- Period low
- $39.90
- Period high
- $44.73
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $40.04 | $40.57 | $39.85 | $40.19 | 312.91K |
| Sep 3, 2026 | $41.30 | $41.30 | $40.085 | $40.47 | 301.27K |
| Sep 2, 2026 | $40.49 | $41.49 | $40.35 | $40.89 | 395.53K |
| Sep 1, 2026 | $39.87 | $41.435 | $39.655 | $40.50 | 651.11K |
| Aug 31, 2026 | $40.48 | $40.8808 | $39.34 | $39.90 | 636.31K |
| Aug 28, 2026 | $41.18 | $41.465 | $40.5094 | $40.95 | 491.25K |
| Aug 27, 2026 | $42.39 | $42.65 | $41.16 | $41.18 | 533.52K |
| Aug 26, 2026 | $43.22 | $43.22 | $42.33 | $42.44 | 313.61K |
| Aug 25, 2026 | $42.95 | $43.25 | $42.53 | $43.22 | 465.74K |
| Aug 24, 2026 | $42.68 | $43.34 | $41.95 | $42.30 | 812.27K |
| Aug 21, 2026 | $42.36 | $42.85 | $41.76 | $42.68 | 647.13K |
| Aug 20, 2026 | $42.83 | $43.48 | $41.68 | $42.11 | 567.69K |
| Aug 19, 2026 | $45.04 | $46.01 | $42.89 | $43.57 | 630.19K |
| Aug 18, 2026 | $43.59 | $45.38 | $43.59 | $44.26 | 549.7K |
| Aug 17, 2026 | $43.75 | $44.3118 | $43.41 | $43.59 | 276.26K |
| Aug 14, 2026 | $44.53 | $44.55 | $43.65 | $44.20 | 276.05K |
| Aug 13, 2026 | $45.34 | $46.1251 | $43.74 | $44.54 | 527.89K |
| Aug 12, 2026 | $44.11 | $44.895 | $43.66 | $44.73 | 290.77K |
| Aug 11, 2026 | $44.30 | $45.27 | $44.0122 | $44.35 | 416.86K |
| Aug 10, 2026 | $44.48 | $44.8231 | $43.15 | $43.95 | 415.81K |
Latest VCEL news
The latest Smart Investors Daily articles mentioning VCEL.
Stock researchCompany · Overview
VCEL research
Overview
Company profile and research snapshot.
Company profile
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $41.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 31, 2026 | TD Cowen | Buy | — |
| Jul 31, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
| Jul 28, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 16, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
ChartMill · Aug 11, 2026
Vericel Corp (NASDAQ:VCEL): Growth at a Reasonable Price
Vericel (VCEL) fits the affordable growth screen with strong EPS/revenue growth, reasonable valuation vs peers, and solid profitability.
Yahoo · Aug 3, 2026
Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison
IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a […]
Benzinga · Jul 31, 2026
TD Cowen Maintains Buy on Vericel, Raises Price Target to $58
TD Cowen analyst Joshua Jennings maintains Vericel (NASDAQ:VCEL) with a Buy and raises the price target from $55 to $58.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
